1. Home
  2. BBCP vs PBYI Comparison

BBCP vs PBYI Comparison

Compare BBCP & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concrete Pumping Holdings Inc.

BBCP

Concrete Pumping Holdings Inc.

HOLD

Current Price

$10.53

Market Cap

367.7M

ML Signal

HOLD

Logo Puma Biotechnology Inc

PBYI

Puma Biotechnology Inc

HOLD

Current Price

$8.54

Market Cap

428.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBCP
PBYI
Founded
1983
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
367.7M
428.1M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
BBCP
PBYI
Price
$10.53
$8.54
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$8.25
N/A
AVG Volume (30 Days)
289.5K
376.3K
Earning Date
06-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$392,867,000.00
$27,685,000.00
Revenue This Year
$4.90
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.56
$3.03
52 Week High
$12.19
$8.66

Technical Indicators

Market Signals
Indicator
BBCP
PBYI
Relative Strength Index (RSI) 49.10 66.22
Support Level $10.39 $6.50
Resistance Level $12.08 N/A
Average True Range (ATR) 0.49 0.38
MACD -0.21 0.02
Stochastic Oscillator 7.78 88.88

Price Performance

Historical Comparison
BBCP
PBYI

About BBCP Concrete Pumping Holdings Inc.

Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: